by Barry101 | Mar 6, 2017 | Press Release
PHILADELPHIA, March 06, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of sales of recently manufactured Ampligen in international...
by Barry101 | Feb 2, 2017 | Press Release
PHILADELPHIA, Feb. 02, 2017 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”), announced today that it has entered into definitive agreements with several institutional investors for an offering of shares of...
by Barry101 | Feb 1, 2017 | Press Release
The attached letter can also be found on the company's website at http://ir.hemispherx.net/Events_Presentations
by Barry101 | Jan 26, 2017 | Press Release
PHILADELPHIA, Jan. 26, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access Program (EAP) in Europe has been shipped with receipt confirmed on January 26....
by Barry101 | Jan 11, 2017 | Press Release
First patient treated in the NetherlandsPHILADELPHIA, Jan. 11, 2017 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that the rintatolimod European early access program (EAP) designed to enable access...
by Barry101 | Nov 21, 2016 | Press Release
PHILADELPHIA, Nov. 21, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it will be presenting at the 9th annual LD Micro Main Event being held on December 6-8, 2016 at the Luxe Sunset...
